Evaluation of glucocorticoid treatment on different pathological types of primary nephrotic syndrome

Y. Zhang, Y Y. Wang, R. Fu, X. Yan

Article ID: 5389
Vol 33, Issue 2, 2019
DOI: https://doi.org/10.54517/jbrha5389
Received: 13 November 2018; Accepted: 13 November 2018; Available online: 9 May 2019; Issue release: 9 May 2019

Abstract

This study aimed to assess the distribution of pathotypes in primary nephrotic syndrome (PNS) and their relationship with glucocorticoid treatment efficacy. The study included 120 patients who were treated in the nephrology, internal medicine and pediatrics wards of The Second Affiliated Hospital of Qiqihar Medical University between March 2014 and October 2017 and who underwent renal biopsy to confirm PNS. The patients with PNS were divided into a child group (40 cases, aged 0~17 years) and an adult group (80 cases, aged over 18 years). We evaluated the correlation of the curative effect of glucocorticoid with age, pathological type, renal tubulointerstitial damage retinol binding protein and total urine protein. The main pathological types of PNS were glomerular minor lesion (GML) and mesangial proliferative nephritis (MPGN). The glucocorticoid treatment had an improved effect on children compared to adults, and also the effect decreased with age. The pathotypes of PNS were correlated with hormone resistance: tubulointerstitial lesions were associated with glucocorticoid resistance which was also associated with the degree of tubular damage. In both adults and children the retinol binding protein (RBP) urinary levels were positively associated with the degree of renal tubular injury. In conclusion, age, pathological type, renal tubulointerstitial damage, and RBP urinary level were related to the therapeutic effect of glucocorticoid treatment in adults and children with PNS.


Keywords

primary nephrotic syndrome;pathotype;glucocorticoids;hormone sensitivity/resistance


References

Supporting Agencies



Copyright (c) 2019 Y. Zhang, Y Y. Wang, R. Fu, X. Yan




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).